BMO Capital Markets Upgrades Envista (NYSE:NVST) to Hold

Envista (NYSE:NVST) was upgraded by stock analysts at BMO Capital Markets to a “hold” rating in a report issued on Wednesday,Zacks.com reports.

NVST has been the topic of several other reports. Evercore reissued an “outperform” rating and issued a $33.00 target price on shares of Envista in a report on Thursday, May 7th. Robert W. Baird upped their price target on shares of Envista from $30.00 to $31.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. Barclays cut their price objective on shares of Envista from $34.00 to $32.00 and set an “overweight” rating on the stock in a research report on Thursday, June 11th. Zacks Research cut shares of Envista from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Finally, Wall Street Zen cut shares of Envista from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Six research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $28.54.

Envista Trading Up 0.0%

NYSE:NVST opened at $25.75 on Wednesday. The firm has a market capitalization of $4.19 billion, a P/E ratio of 62.80, a PEG ratio of 1.46 and a beta of 0.86. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.44 and a quick ratio of 2.06. Envista has a one year low of $18.77 and a one year high of $30.42. The company’s 50-day simple moving average is $24.84 and its 200 day simple moving average is $25.42.

Envista (NYSE:NVST) last announced its earnings results on Wednesday, May 6th. The company reported $0.36 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.05. The business had revenue of $705.50 million during the quarter, compared to the consensus estimate of $680.03 million. Envista had a net margin of 2.41% and a return on equity of 7.11%. The business’s revenue for the quarter was up 14.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.24 earnings per share. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. As a group, analysts forecast that Envista will post 1.42 EPS for the current fiscal year.

Hedge Funds Weigh In On Envista

Hedge funds have recently bought and sold shares of the business. Dimensional Fund Advisors LP boosted its holdings in shares of Envista by 1.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 9,780,948 shares of the company’s stock valued at $248,130,000 after acquiring an additional 152,488 shares during the last quarter. Alliancebernstein L.P. lifted its position in Envista by 34.0% during the second quarter. Alliancebernstein L.P. now owns 6,098,445 shares of the company’s stock valued at $119,164,000 after purchasing an additional 1,547,656 shares during the period. Massachusetts Financial Services Co. MA lifted its position in Envista by 15.3% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 3,349,874 shares of the company’s stock valued at $72,726,000 after purchasing an additional 444,725 shares during the period. Arrowstreet Capital Limited Partnership boosted its holdings in Envista by 341.5% in the first quarter. Arrowstreet Capital Limited Partnership now owns 2,858,293 shares of the company’s stock worth $72,515,000 after purchasing an additional 2,210,847 shares during the last quarter. Finally, Quantinno Capital Management LP grew its position in Envista by 38.8% in the 1st quarter. Quantinno Capital Management LP now owns 2,694,970 shares of the company’s stock worth $68,371,000 after purchasing an additional 753,474 shares during the period.

Envista Company Profile

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.